The Trump-Vance and Harris-Walz presidential campaigns have each recently proposed large expansions to the child tax credit (CTC). Both proposals might be intended to appeal to similar voters, but they vary significantly regarding budgetary cost, distribution of benefits, and effect on work incentives.
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
“If Republicans take control of Congress in this fall’s election, protecting previously passed policies will be among the party’s top priority, said Alex Brill, a senior fellow at the American Enterprise Institute for Public Policy Research, a conservative think tank based in Washington, D.C. “
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.
In his article for Intellectual Asset Management (IAM), Life Sciences Reporter Adam Houldsworth discusses the weaknesses in the US patent system that enable the “thorny” problem of patent thickets. MGA’s report, “How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” was featured heavily in the article to provide evidence of the growing problem.
